Related Experiment Videos
The Mpl ligand and platelet homeostasis
1Department of Pharmacology, Amgen Inc., Thousand Oaks, California, USA.
Acta Paediatrica (Oslo, Norway : 1992). Supplement
|September 15, 1998
Summary
Researchers explored thrombopoietin (TPO) and its receptor Mpl to understand platelet production. Studies in vitro, in vivo, and clinical trials reveal insights into TPO
Area of Science:
- Hematology
- Molecular Biology
- Pharmacology
Background:
- Mpl, a cytokine receptor on platelet lineage cells, has had its ligand identified and cloned.
- This has significantly advanced understanding of megakaryopoiesis, thrombopoiesis, and endogenous Mpl ligand (thrombopoietin, eTPO) regulation.
Purpose of the Study:
- To review in vitro and in vivo data on Mpl ligand (thrombopoietin, TPO) in human and non-human primates.
- To discuss early results from clinical trials of two recombinant TPO (rTPO) forms.
- To provide insights into the biology of response to exogenous rTPO for therapeutic applications.
Main Methods:
- Review of in vitro human and non-human primate data.
- Analysis of preclinical (in vivo) non-human primate studies.
- Examination of early clinical trial results for recombinant TPO (rTPO).
Main Results:
- Accumulation of data on megakaryopoiesis and thrombopoiesis regulation by TPO.
- Preclinical and clinical studies provide insights into exogenous rTPO response biology.
- Early clinical trial data on rTPO is under review.
Conclusions:
- Understanding platelet production biology and target cell conditions is crucial for therapeutic rTPO use.
- Exogenous rTPO shows potential as a therapeutic agent for platelet production disorders.
- Further research and clinical evaluation are necessary to optimize rTPO therapy.